Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs ResMed Inc. — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.22 (market cap $17.89B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days and ResMed Inc. for 51 Days on average.
| HYG | RMD | |
|---|---|---|
Market Cap | $17.89B | $31.89B |
Volume | 44,866,592 | 618,314 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $277.88 |
52-Week Low | $76.90 | $182.82 |
Typical Hold Time | 60 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.23 with minimal daily movement (+0.06%), showing stability amid broader market volatility. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators suggest potential stabilization. Recent dividend payments provide consistent income, with the latest $0.38 distribution paid in August 2026. The fund faces headwinds from rising Treasury yields and bond market volatility, with key technical indicators showing mixed signals between short-term stabilization and longer-term bearish momentum.
High yield bond ETFs like HYG face pressure from rising interest rates and inflation concerns, though the fund's diversified corporate bond portfolio offers yield advantages over Treasury securities. The current environment presents both income opportunities through attractive yields and risks from potential credit deterioration if economic conditions worsen. Investors should weigh the fund's income generation against interest rate sensitivity and credit risk exposure in the current tightening cycle.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
